Compare SEMR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEMR | NVAX |
|---|---|---|
| Founded | 2008 | 1987 |
| Country | United States | United States |
| Employees | 1561 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.1B |
| IPO Year | 2021 | 1995 |
| Metric | SEMR | NVAX |
|---|---|---|
| Price | $11.86 | $6.82 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 8 |
| Target Price | ★ $13.80 | $9.75 |
| AVG Volume (30 Days) | 1.2M | ★ 3.1M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | $428,627,000.00 | ★ $1,064,651,000.00 |
| Revenue This Year | $20.35 | $58.91 |
| Revenue Next Year | $14.87 | N/A |
| P/E Ratio | ★ N/A | $3.30 |
| Revenue Growth | 19.87 | ★ 20.27 |
| 52 Week Low | $6.56 | $5.01 |
| 52 Week High | $18.74 | $11.55 |
| Indicator | SEMR | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 79.90 | 47.95 |
| Support Level | $11.84 | $6.36 |
| Resistance Level | $11.88 | $7.00 |
| Average True Range (ATR) | 0.03 | 0.22 |
| MACD | -0.16 | 0.07 |
| Stochastic Oscillator | 25.00 | 66.67 |
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.